Cover Image
市場調查報告書

在PharmaPoint:B型肝炎病毒(HBV)預防疫苗--歐洲主要5個國家的醫藥品的預測與市場分析

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 298833
出版日期 內容資訊 英文 191 Pages
訂單完成後即時交付
價格
Back to Top
在PharmaPoint:B型肝炎病毒(HBV)預防疫苗--歐洲主要5個國家的醫藥品的預測與市場分析 PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022
出版日期: 2014年01月31日 內容資訊: 英文 191 Pages
簡介

全球有20億人感染B型肝炎病毒(HBV),每年都有60萬人因B型肝炎相關肝疾病而死亡。自混合HBsAg疫苗出現以來,這二十年來大幅減輕了這個疾病帶來的負擔,但仍留有成人的疫苗攝取及有效性(尤其是特殊病患上)的問題。一般認為今後高風險成人患者的高血清轉換率的達成、各國政策上的對策──歐洲各國新核准的成人疫苗、定期預防接種計劃的實行等──都會推動市場的成長。同時英國資金供給機制未達完善及醫師教育的缺乏、患者方面意願的低落等,都會限制成人疫接種率。

本報告提供EU主要5個國家與(法國·德國·義大利·西班牙·英國)的B型肝炎病毒(HBV)預防疫苗相關的最新研究·開發情形及相關市場未來展望分析,彙整疾病概要和治療方法,市場機會及未滿足需求,市場規模趨勢(今後10年份),現在銷售中及臨床實驗中主要的疫苗簡介,各國市場的現狀與今後的方向性等資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 概要
  • 病因與病情
    • 病因
    • 病理
  • 症狀
  • 預測

第4章 疫苗的接種宣導與攝取率

  • 概要
  • 法國
    • 預防接種的建議與政策
    • 攝取率
    • 臨床診療
  • 德國
  • 義大利
  • 西班牙
  • 英國

第5章 競爭環境

  • 概要
  • 競爭企業的策略性評估
  • 產品簡介:單價疫苗
    • Engerix-B
    • Recombivax HB
    • Fendrix
  • 產品簡介:混合疫苗
    • Infanrix Hexa
    • Hexyon
    • Twinrix
    • Ambirix

第6章 市場機會及未滿足需求

  • 概要
  • 疫苗免疫抗原性的增加
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 疫苗接種率的上升
  • 患者意識的提升
  • 醫生教育的改善
  • 成本效益高的疫苗

第7章 開發平台分析

  • 概要
  • 臨床實驗後期階段產品中的有潛力疫苗
    • Heplisav
  • 臨床實驗初期階段產品中的有潛力疫苗

第8章 市場預測

  • 法國
    • 市場預測
    • 主要趨勢
    • 市場促進·阻礙因素
  • 德國
  • 義大利
  • 西班牙
  • 英國

第9章 附錄

圖表一覽

目錄
Product Code: GDHC215CFR

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

GlobalData's primary and secondary research has revealed that the reimbursement of Infanrix Hexa, which began in 2008, has helped France's routine HBV immunization program recover from safety concerns (CTV, 2012; Denis et al., 2013). The adult HBV vaccine market in Germany is also expected to grow during the forecast period, led by the arrival of Dynavax Technologies' Heplisav in the second half of 2018. GSK dominated Italy's HBV vaccine market in 2012. Sanofi Pasteur MSD's monovalent vaccine, HBVaxPro, accounted for the remaining market share. More specifically, GlobalData expects the arrival of Sanofi Pasteur MSD's Hexyon to be the principal driver of Spain's market growth, as it should compete with Infanrix Hexa for market share in the routine immunization program. GlobalData's primary research has revealed that challenging barriers to growth, such as poor funding mechanisms due to government spending concerns, inadequate physician education, and low patient awareness, will limit adult vaccine uptake and growth of this segment of the market in the UK.

Scope

  • Overview of Hepatitis B disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Hepatitis B disease market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in 5EU

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Overview
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology
  • 3.3. Symptoms
  • 3.4. Prognosis

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Overview
  • 4.2. France
    • 4.2.1. Immunization Recommendations and Policies
    • 4.2.2. Vaccination Coverage
    • 4.2.3. Clinical Practice
  • 4.3. Germany
    • 4.3.1. Immunization Recommendations and Policies
    • 4.3.2. Vaccination Coverage
    • 4.3.3. Clinical Practice
  • 4.4. Italy
    • 4.4.1. Immunization Recommendations and Policies
    • 4.4.2. Vaccination Coverage
    • 4.4.3. Clinical Practice
  • 4.5. Spain
    • 4.5.1. Immunization Recommendations and Policies
    • 4.5.2. Vaccination Coverage
    • 4.5.3. Clinical Practice
  • 4.6. UK
    • 4.6.1. Immunization Recommendations and Policies
    • 4.6.2. Vaccination Coverage
    • 4.6.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Monovalent Vaccines
    • 5.3.1. Engerix-B
    • 5.3.2. Recombivax HB
    • 5.3.3. Fendrix
  • 5.4. Product Profiles - Combination Vaccines
    • 5.4.1. Infanrix Hexa
    • 5.4.2. Hexyon
    • 5.4.3. Twinrix
    • 5.4.4. Ambirix

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Increased Vaccine Immunogenicity
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Increased Vaccination Coverage Rates
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Increased Patient Awareness
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Improved Physician Education
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. More Cost-Effective Vaccines
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Vaccines in Late-Stage Clinical Development
    • 7.2.1. Heplisav
  • 7.3. Promising Vaccines in Early-Stage Clinical Development

8. Market Outlook

  • 8.1. France
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers
  • 8.2. Germany
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Drivers and Barriers
  • 8.3. Italy
    • 8.3.1. Forecast
    • 8.3.2. Key Events
    • 8.3.3. Drivers and Barriers
  • 8.4. Spain
    • 8.4.1. Forecast
    • 8.4.2. Key Events
    • 8.4.3. Drivers and Barriers
  • 8.5. UK
    • 8.5.1. Forecast
    • 8.5.2. Key Events
    • 8.5.3. Drivers and Barriers
    • 8.5.4. Alternative Market Scenario

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Patient Populations Targeted for Vaccination
    • 9.4.2. Vaccination Coverage Rates
    • 9.4.3. Vaccinated Patients
    • 9.4.4. Regulatory Approval vs. Advisory Committee Recommendation
    • 9.4.5. Vaccines Included
    • 9.4.6. Key Launch Dates
    • 9.4.7. General Pricing Assumptions
    • 9.4.8. Individual Vaccine Assumptions
    • 9.4.9. Pricing of Pipeline Vaccines
  • 9.5. Physicians and Specialists Included in this Study
    • 9.5.1. Interviews of Key Opinion Leaders (KOLs)
    • 9.5.2. Online Survey of High-Prescribing Physicians (non-KOLs)
  • 9.6. About the Authors
    • 9.6.1. Analyst
    • 9.6.2. Therapy Area Director
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Modes of HBV Transmission
  • Table 2: HBV Serological Markers and Test Interpretations
  • Table 3: Symptoms of HBV Infection
  • Table 4: HBV Vaccination Advisory Committees by Country
  • Table 5: HBV Immunization Recommendations by Country
  • Table 6: Targeted Age Group(s) for Routine Immunization and Most Administered HBV Vaccines by Country in the Global Markets, 2014
  • Table 7: Leading Vaccines for HBV, 2014
  • Table 8: Product Profile - Engerix-B
  • Table 9: Immunogenicity Profile - Engerix-B
  • Table 10: Safety Profile - Engerix-B
  • Table 11: Engerix-B SWOT Analysis, 2014
  • Table 12: Product Profile - Recombivax HB
  • Table 13: Immunogenicity Profile - Recombivax HB
  • Table 14: Safety Profile - Recombivax HB
  • Table 15: Recombivax HB SWOT Analysis, 2014
  • Table 16: Product Profile - Fendrix
  • Table 17: Immunogenicity Profile - Fendrix
  • Table 18: Safety Profile - Fendrix
  • Table 19: Fendrix SWOT Analysis, 2014
  • Table 20: Product Profile - Infanrix Hexa
  • Table 21: Immunogenicity Profile - Infanrix Hexa
  • Table 22: Safety Profile - Infanrix Hexa
  • Table 23: Infanrix Hexa SWOT Analysis, 2014
  • Table 24: Product Profile - Hexyon
  • Table 25: Immunogenicity Profile - Hexyon
  • Table 26: Safety Profile - Hexyon
  • Table 27: Hexyon SWOT Analysis, 2014
  • Table 28: Product Profile - Twinrix
  • Table 29: Immunogenicity Profile - Twinrix
  • Table 30: Safety Profile - Twinrix
  • Table 31: Twinrix SWOT Analysis, 2014
  • Table 32: Product Profile - Ambirix
  • Table 33: Immunogenicity Profile - Ambirix
  • Table 34: Safety Profile - Ambirix
  • Table 35: Ambirix SWOT Analysis, 2014
  • Table 36: Unmet Need and Opportunity in Prophylactic HBV Vaccines
  • Table 37: HBV Vaccines - Phase Pipeline, 2014
  • Table 38: Comparison of Vaccines in Development for HBV, 2014
  • Table 39: Product Profile - Heplisav
  • Table 40: Immunogenicity Profile - Heplisav
  • Table 41: Safety Profile - Heplisav
  • Table 42: Heplisav SWOT Analysis, 2014
  • Table 43: Sales Forecasts ($m) for HBV Vaccines in France, 2012-2022
  • Table 44: Key Events Impacting Sales for HBV Vaccines in France, 2014
  • Table 45: France HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 46: Sales Forecasts ($m) for HBV Vaccines in Germany, 2012-2022
  • Table 47: Key Events Impacting Sales for HBV Vaccines in Germany, 2014
  • Table 48: Germany HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 49: Sales Forecasts ($m) for HBV Vaccines in Italy, 2012-2022
  • Table 50: Key Events Impacting Sales for HBV Vaccines in Italy, 2014
  • Table 51: Italy HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 52: Sales Forecasts ($m) for HBV Vaccines in Spain, 2012-2022
  • Table 53: Key Events Impacting Sales for HBV Vaccines in Spain, 2014
  • Table 54: Spain HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 55: Sales Forecasts ($m) for HBV Vaccines in the United Kingdom, 2012-2022
  • Table 56: Key Events Impacting Sales for HBV Vaccines in the United Kingdom, 2014
  • Table 57: United Kingdom HBV Vaccine Market - Drivers and Barriers, 2014
  • Table 58: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, by Country
  • Table 59: Patient Population(s) Targeted for HBV Vaccination in the Adult Market, by Country
  • Table 60: Key Launch Dates
  • Table 61: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: HBV Structure and the Recombinant Vaccine Development Process
  • Figure 2: Routine HBV Vaccination Coverage (%) in France
  • Figure 3: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in France, 2014
  • Figure 4: Routine HBV Vaccination Coverage (%) in Germany
  • Figure 5: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Germany, 2014
  • Figure 6: Routine HBV Vaccination Coverage (%) in Italy
  • Figure 7: High-Prescriber Estimation of Pediatric HBV Patient Share in Italy, 2014
  • Figure 8: Routine HBV Vaccination Coverage (%) in Spain
  • Figure 9: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Spain, 2014
  • Figure 10: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in the United Kingdom, 2014
  • Figure 11: Competitive Assessment of Late-Stage Pipeline Agents and Marketed Products in HBV Vaccines, 2012-2022
  • Figure 12: Sales for HBV Vaccines in France, 2012-2022
  • Figure 13: Sales for HBV Vaccines in Germany, 2012-2022
  • Figure 14: Sales for HBV Vaccines in Italy, 2012-2022
  • Figure 15: Sales for HBV Vaccines in Spain, 2012-2022
  • Figure 16: Sales for HBV Vaccines in the United Kingdom, 2012-2022
Back to Top